Abstract
Treatment with inhibitors of 3-hydroxyl-3-methylglutaryl coenzyme A reductase (statins) reduces the incidence of cardiovascular events, but it is unclear whether the beneficial effects are mediated solely by their lipid-lowering properties. We therefore investigated whether atorvastatin reduces inflammation and oxidative stress independently of its lipid-lowering effects. The subjects comprised 71 hyperlipidemic patients (64 ± 9 years old, mean ± SD) who were not receiving medical treatment. Serum lipid and C-reactive protein (CRP) levels, and urine 8-isoprostane level (an index of oxidative stress) were measured before and after 4 weeks of treatment with atorvastatin at 10 mg/day. In 38 patients, these biochemical variables and carotid intima-media thickness (IMT) were also measured after 6 months of treatment with atorvastatin. Atorvastatin markedly reduced CRP (from 0.69 ± 0.36 to 0.42 ± 0.20 and 0.35 ± 0.19 mg/l, median ± median absolute deviation, P < 0.0001), 8-isoprostane (from 225 ± 99 to 178 ± 75 and 179 ± 60 ng/g creatinine, P < 0.05), and low density-lipoprotein cholesterol (LDLC; from 165 ± 21 to 106 ± 18 and 112 ± 17 mg/dl, P < 0.0001) after 4 weeks and 6 months of treatment, respectively. However, the reductions in CRP and 8-isoprostane were not correlated with those of LDLC. After 6 months of treatment, IMT was significantly decreased compared with the baseline value (from 0.94 ± 0.26 to 0.90 ± 0.20 mm, P < 0.05), but this was not correlated with the reduction in LDLC. These results suggest that atorvastatin has beneficial effects on inflammation, oxidative stress, and the lipid profile in patients with hyperlipidemia. The extra-lipid effects are not attributable to the lipid-lowering effect of the statin, suggesting that the pleiotropic effects of atorvastatin are independent of its effects on the lipid profile.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
U Gresser BS Gathof (2004) ArticleTitleAtorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke – comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies Eur J Med Res 9 1–17
JA Farmer (2000) ArticleTitlePleiotropic effects of statins Curr Atheroscler Rep 2 208–217
M Takemoto JK Liao (2001) ArticleTitlePleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors Arterioscler Thromb Vasc Biol 21 1712–1719
MA Albert E Danielson N Rifai PM Ridker InstitutionalAuthorNamePRINCE Investigators (2001) ArticleTitleEffect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 64–70
RS Rosenson W Koenig (2003) ArticleTitleUtility of inflammatory markers in the management of coronary artery disease Am J Cardiol 92 10i–18i
PM Ridker (2003) ArticleTitleHigh-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention Am J Cardiol 92 17K–22K
S Kinlay GG Schwartz AG Olsson N Rifai SJ Leslie WJ Sasiela M Szarek P Libby P Ganz InstitutionalAuthorNameMyocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators (2003) ArticleTitleHigh-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study Circulation 108 1560–1566
H Nawawi NS Osman K Yusoff BA Khalid (2003) ArticleTitleReduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia Horm Metab Res 35 479–485
RP Byington BR Davis JF Plehn HD White J Baker SM Cobbe J Shepherd (2001) ArticleTitleReduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project Circulation 103 387–392
RW Alexander (1995) ArticleTitleTheodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective Hypertension 25 155–161
JT Willerson PM Ridker (2004) ArticleTitleInflammation as a cardiovascular risk factor Circulation 109 IssueIDs1 I2–II10
K Uehara M Nomura Y Ozaki H Fujinaga H Ikefuji M Kimura K Chikamori Y Nakaya S Ito (2003) ArticleTitleHigh-sensitivity C-reactive protein and left ventricular remodeling in patients with acute myocardial infarction Heart Vessels 18 67–74
M Tokac A Ozeren M Aktan BB Altunkeser K Ozdemir A Duzenli H Gok (2003) ArticleTitleThe role of inflammation markers in triggering acute coronary events Heart Vessels 18 171–176
SM Kent PJ Flaherty LC Coyle TT Markwood AJ Taylor (2003) ArticleTitleEffect of atorvastatin and pravastatin on serum C-reactive protein Am Heart J 145 e8
BJ Ansell KE Watson RE Weiss GC Fonarow (2003) ArticleTitlehsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels. A clinical investigation Heart Dis 5 2–7
DR Matthews JP Hosker AS Rudenski BA Naylor DF Treacher RC Turner (1985) ArticleTitleHomeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 412–419
P Pignoli E Tremoli A Poli P Oreste R Paoletti (1986) ArticleTitleIntimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging Circulation 74 1399–1406
P Libby PM Ridker A Maseri (2002) ArticleTitleInflammation and atherosclerosis Circulation 105 1135–1143
S van Wissen TJ Smilde E de Groot BA Hutten JJ Kastelein AF Stalenhoef (2003) ArticleTitleThe significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study Eur J Cardiovasc Prev Rehabil 10 451–455
M Yamaoka-Tojo T Tojo T Masuda Y Machida Y Kitano T Kurosawa T Izumi (2003) ArticleTitleC-reactive protein-induced production of interleukin-18 in human endothelial cells: a mechanism of orchestrating cytokine cascade in acute coronary syndrome Heart Vessels 18 183–187
RJ Gryglewski RM Palmer S Moncada (1986) ArticleTitleSuperoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor Nature 320 454–456
DG Harrison (1997) ArticleTitleEndothelial function and oxidative stress Clin Cardiol 20 IssueIDs2 II11–II17
J Ejiri N Inoue T Tsukube T Munezane Y Hino S Kobayashi K Hirata S Kawashiwa S Imajoh-Ohmi Y Hayashi H Yokozaki Y Okita M Yokoyama (2003) ArticleTitleOxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker Cardiovasc Res 59 988–996
M Aviram M Rosenblat CL Bisgaier RS Newton (1998) ArticleTitleAtorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation Atherosclerosis 138 271–280
S Wolfrum KS Jensen JK Liao (2003) ArticleTitleEndothelium-dependent effects of statins Arterioscler Thromb Vasc Biol 23 729–736
S Wassmann N Ribaudo A Faul U Laufs M Bohm G Nickenig (2004) ArticleTitleEffect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels <130 mg/dl Am J Cardiol 93 84–88
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sugiyama, M., Ohashi, M., Takase, H. et al. Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels 20, 133–136 (2005). https://doi.org/10.1007/s00380-005-0833-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00380-005-0833-9